Trials / Completed
CompletedNCT03122041
Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University Medical Centre Ljubljana · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events. The alternative pharmacological strategy when metformin cannot be tolerated is not well established in this population. Our aim was to evaluate whether sitagliptin (SITA) preserves metabolic profile in metformin (MET) intolerant PCOS with high metabolic risk.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | |
| BEHAVIORAL | Lifestyle intervention |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2017-04-20
- Last updated
- 2017-04-20
Source: ClinicalTrials.gov record NCT03122041. Inclusion in this directory is not an endorsement.